*Disclaimer

IMMUTEP LIMITED (ASX: IMM)

🔗 📄 📈

IMM: US patent granted for Efti with PD-1 pathway inhibitor

IMMUTEP LIMITED

2023-06-27 14:37:00

IMM: Immutep completes underwritten retail entitlement offer

IMMUTEP LIMITED

2023-06-27 08:16:00

IMM: Immutep granted US patent for IMP761 agonist LAG-3 antibody

IMMUTEP LIMITED

2023-06-20 14:43:00

IMM: Immutep completes institutional pro-rata offer & placement

IMMUTEP LIMITED

2023-06-02 09:02:00

IMM: A$80 million fully underwritten equity raising

IMMUTEP LIMITED

2023-05-31 09:38:00

IMM: Charles River Laboratories to run IMP761 Toxicology Study

IMMUTEP LIMITED

2023-05-29 08:20:00

IMM: Publication of Abstracts for ASCO 2023 Annual Meeting

IMMUTEP LIMITED

2023-05-26 08:24:00

IMM: 1st patient dosed in AIPAC-003 ph2/3 breast cancer trial

IMMUTEP LIMITED

2023-05-25 08:19:00

IMM: Promising New Data in 1st line NSCLC from INSIGHT-003 Trial

IMMUTEP LIMITED

2023-05-24 09:01:00

IMM: Excellent initial Overall Survival Benefit in 1st line NSCLC

IMMUTEP LIMITED

2023-05-17 09:02:00

IMM: FDA supportive of Efti registrational trial in lung cancer

IMMUTEP LIMITED

2023-05-16 08:18:00

IMM: Approval to start Efti & Bavencio trial in urothelial cancer

IMMUTEP LIMITED

2023-05-01 08:12:00

IMM: Immutep to announce new TACTI-002 data at ASCO 2023

IMMUTEP LIMITED

2023-04-27 08:02:00

IMM: Initiation of Phase 2 Trial for Efti in Soft Tissue Sarcoma

IMMUTEP LIMITED

2023-04-17 08:24:00

IMM: Positive Final Data in 2nd Line Metastatic NSCLC Patients

IMMUTEP LIMITED

2023-03-31 17:47:00

IMM: Expansion of INSIGHT-003 trial for Efti in 1st Line NSCLC

IMMUTEP LIMITED

2023-03-30 09:57:00

IMM: Initiation of Ph 2/3 Trial for Metastatic Breast Cancer

IMMUTEP LIMITED

2023-03-14 08:11:00

IMM: Enrolment Target Reached for INSIGHT-003 Trial in NSCLC

IMMUTEP LIMITED

2023-02-06 08:48:00

IMM: TACTI-003 trial 50% enrolment milestone has been achieved

IMMUTEP LIMITED

  1. Immutep Limited (ASX: IMM; NASDAQ: IMMP) has enrolled and randomised over 50% of the planned 154 patients in the TACTI -003 Phase IIb trial.
  2. TACTI -003 is evaluating Immutep’s first-in-class soluble LAG-3 protein eftilagimod alpha (“efti”) in combination with MSD’s anti-PD-1 therapy KEYTRUDA® as 1st line treatment of recurrent or metastatic head and neck squamous cell carcinoma (1L HNSCC).
  3. Marc Voigt, CEO of Immutep stated: “We are pleased to reach this important milestone and extend our sincere appreciation to our investigators, clinical team, partners, and patients for their hard work and commitment to this study.”

2023-01-04 08:19:00